Key Takeaways

From the Authors As published in the article
  1. There is very little research on heated yoga for the treatment of depression, and treatment options for depression are sorely lacking; we therefore conducted a randomized controlled trial of heated yoga for depression.
  2. Heated yoga appears to be associated with a reduction in depressive symptoms over an 8-week period when compared to a waitlist control intervention.
  3. Heated yoga at a frequency of approximately 1 class per week could be a viable treatment option for medicated and unmedicated patients with moderate-to-severe depression.
Extended Takeaways
  1. At 8 weeks, heated yoga produced a large between-group advantage on the clinician-rated IDS-CR (Cohen d = 1.04, P < .001), with a faster rate of symptom reduction than waitlist in the repeated-measures model (time × arm effect: b = −3.09, P < .001).
  2. Clinical benefit was reflected not only in mean symptom change but also in categorical outcomes: 59.3% (n = 16) of yoga participants met response criteria and 44% (n = 12) remitted, compared with 6.3% (n = 2) for both outcomes in the waitlist arm.
  3. The antidepressant signal was not limited to patients off medication; antidepressant use status did not significantly alter the effect of randomization on IDS-CR over time (time × arm × antidepressant use: b = 0.99, P = .31).
  4. Attendance fell short of the prescribed dose, yet outcomes still improved: participants attended 10.3 ± 7.1 classes over 8 weeks, and only 36% (n = 12) reached ≥ 12 classes, suggesting this community-delivered format may still be clinically useful even when adherence is imperfect.
  5. Safety findings were reassuring for a vigorous 105°F intervention: among yoga participants, only 1 intervention-related adverse event beyond the probably related events was reported as mild, and no serious adverse events (SAEs) were reported.
  6. Baseline illness severity mattered for retention, as higher HDRS-17 scores predicted lower likelihood of inclusion in analyses and/or completing the end-of-treatment clinician assessment (OR = 0.88 [95% CI = 0.78 to 0.99], P = .04); more severely depressed patients may need added support to stay engaged.
Read full article
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe